This not published peer reviewed evidence - it is a presentation. Worse still, it is stated to be a randomised, double-blind controlled trial yet most of their results only show the effect of Ropren - no control data is given???? Surely even the SLA true believers can see through this glaring omission? Adding to this none of their data points on their graphs have error bars nor has any statistical analysis been done. This doesn't even rate as F grade science. They are intentialy misleading the public and investors. Solascam
SLA Price at posting:
0.0¢ Sentiment: LT Sell Disclosure: Not Held
